Crossmark

Bleeding risk in patients with autosomal dominant polycystic kidney disease treated with acetylsalicylic acid: implications for prevention of preeclampsia

Crossref DOI link: https://doi.org/10.1007/s40620-022-01393-y

Published Online: 2022-07-13

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

de Jong, M. F. C. https://orcid.org/0000-0001-7347-4344
Komdeur, H. M.

Salih, M. https://orcid.org/0000-0002-4568-8967
Meijer, E. https://orcid.org/0000-0001-7875-1793
,

Drenth, Joost P. H.

Fijter, Johan W.

Gansevoort, Ron T.

Meijer, Esther

Peters, Dorien J. M.

Wetzels, Jack F.

Zietse, Robert
Funding

Funding for this research was provided by:

Nierstichting (CP10.12)

Nierstichting (CP15.01)

Ministerie van Economische Zaken (TKI LSHM 15018)
License Information

Text and Data Mining valid from 2022-07-13

Version of Record valid from 2022-07-13
More Information

Article History

Received: 3 May 2022

Accepted: 22 June 2022

First Online: 13 July 2022

Declarations

:

: The DIPAK Consortium is sponsored by the Dutch Kidney Foundation (Grants CP10.12 and CP15.01) and the Ministry of Economic Affairs by means of the PPP Allowance made available by the Top Sector Life Sciences & Health to stimulate public–private partnerships (TKI LSHM 15018).

: All authors declare that they have no conflicts of interest.

Document is current

Any future updates will be listed below